UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial

Toxins, 2021-03, Vol.13 (4), p.235

2021

Volltextzugriff (PDF)

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

American journal of hematology, 2023-06, Vol.98 (6), p.900-912

2023

Volltextzugriff (PDF)

Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)

Discover. Oncology, 2022-10, Vol.13 (1), p.105-13, Article 105

2022

Volltextzugriff (PDF)

Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients

Journal of neuro-oncology, 2006-05, Vol.78 (1), p.99-102

2006

Volltextzugriff (PDF)

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma

The oncologist (Dayton, Ohio), 2024-10

2024

Volltextzugriff (PDF)

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Neuro-oncology advances, 2024-01, Vol.6 (1), p.vdae009-vdae009

2024

Volltextzugriff (PDF)

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Leukemia & lymphoma, 2023-04, Vol.64 (5), p.1026-1034

2023

Volltextzugriff (PDF)

Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma

Neuro-oncology advances, 2024-01, Vol.6 (1), p.vdae129

2024

Volltextzugriff (PDF)

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply

The lancet oncology, 2017-12, Vol.18 (12), p.e709-e710

2017

Volltextzugriff (PDF)

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1373-1385

2017

Volltextzugriff (PDF)

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas

Science advances, 2022-06, Vol.8 (25), p.eabn3471

2022

Volltextzugriff (PDF)

Randomized prospective comparison of forced air warming using hospital blankets versus commercial blankets in surgical patients

Anesthesiology (Philadelphia), 2002-08, Vol.97 (2), p.338-344

2002

Volltextzugriff (PDF)

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

Journal of neuro-oncology, 2012-04, Vol.107 (2), p.407-411

2012

Volltextzugriff (PDF)

The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2084-TPS2084

2022

Volltextzugriff (PDF)

Headache in Patients with Cancer

Current pain and headache reports, 2010-12, Vol.14 (6), p.455-464

2010

Volltextzugriff (PDF)

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Journal of translational medicine, 2018-05, Vol.16 (1), p.142-142, Article 142

2018

Volltextzugriff (PDF)

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial

JAMA oncology, 2023-01, Vol.9 (1), p.112

2023

Volltextzugriff (PDF)

Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2047-2047

2022

Volltextzugriff (PDF)

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2077-TPS2077

2022

Volltextzugriff (PDF)

Abstract CT258: EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT258-CT258

2021

Volltextzugriff (PDF)

Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB125-LB125

2021

Volltextzugriff (PDF)

Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT205-CT205

2020

Volltextzugriff (PDF)

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)

Neuro-oncology advances, 2022-08, Vol.4 (Supplement_1), p.i7-i8

2022

Volltextzugriff (PDF)

Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT061-CT061

2023

Volltextzugriff (PDF)

10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Neuro-oncology advances, 2023-12, Vol.5 (Supplement_5), p.v2-v2

2023

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(71)

Sprache

Englisch
(71)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)

Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas

Randomized prospective comparison of forced air warming using hospital blankets versus commercial blankets in surgical patients

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors

The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields

Headache in Patients with Cancer

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial

Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study

Abstract CT258: EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status

Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)

Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma

10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Suchergebnisse filtern